Powder: -20°C for 3 years
In solvent: -80°C for 2 years
GSK1940029 is a stearoyl-coa desaturase (SCD) inhibitor.
Description | GSK1940029 is a stearoyl-coa desaturase (SCD) inhibitor. |
In vitro | GSK1940029 is a stearoyl-coa desaturase (SCD) , methods of synthesis and uses ?in treating and/or preventing various diseases, including those mediated by SCD enzyme, such as diseases related to elevated lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome, skin disorders such as acne, diseases or conditions related to cancer. |
Synonyms | SCD inhibitor 1 |
Molecular Weight | 391.25 |
Formula | C18H16Cl2N4O2 |
CAS No. | 1150701-66-8 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 30 mg/mL (76.67 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK1940029 1150701-66-8 Metabolism Stearoyl-CoA Desaturase (SCD) Dehydrogenase Alzheimer's cancer SCD inhibitor-1 SCD inhibitor 1 cardiovascular,diabetes inhibit obesity SCD inhibitor1 metabolic GSK 1940029 elevated GSK-1940029 Inhibitor syndrome SCD enzyme inhibitor